TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35716332

Group type: EXPERIMENTAL
Intervention: Difamilast 1% ointment (adults)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Difamilast 0.3% ointment (pediatrics)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Difamilast 1% ointment (pediatrics)
Number of subjects: 366
Study: 35716543

Group type: EXPERIMENTAL
Intervention: CPAP adherence (≥4 hours for ≥70% of nights over 3 months)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Baseline demographic and stroke-related factors
Number of subjects: 52

Group type: COMPARATOR
Intervention: Early CPAP complaints
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Facilitators of adherence
Number of subjects: 52

Group type: COMPARATOR
Intervention: Barriers to adherence
Number of subjects: 52
Study: 35716700

Group type: EXPERIMENTAL
Intervention: BioFire Global Fever Panel (GF Panel)
Number of subjects: 1965
Study: 35716871

Group type: EXPERIMENTAL
Intervention: Transvaginal graft (Xenform)
Number of subjects: 713

Group type: COMPARATOR
Intervention: Native tissue repair
Number of subjects: 713
Study: 35717027

Group type: EXPERIMENTAL
Intervention: Guadecitabine (30 mg/m²) in combination with pembrolizumab
Number of subjects: 34
Study: 35717147

Group type: EXPERIMENTAL
Intervention: EEG polysomnography and sleep actigraphy in infants with AD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Standardized severity assessment tools for AD
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessment at 18 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Monthly questionnaires on sleep and parental sleep
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Skin barrier and immune profiles at six-eight and 12 months
Number of subjects: 50
Study: 35717179

Group type: EXPERIMENTAL
Intervention: Higher degree of pain severity
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Higher degree of disability
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Higher degree of depression
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Lower degree of physical health-related quality of life
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Kinesiophobia
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Recovery expectations
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Radiating pain below the knee
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Mental health-related quality of life
Number of subjects: 1127
Study: 35717182

Group type: EXPERIMENTAL
Intervention: Ulcerative OLP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Erythematous OLP
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reticular OLP
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study: 35717381

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 5609

Group type: EXPERIMENTAL
Intervention: Asymptomatic gene carriers
Number of subjects: 5609
Study: 35717608

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Beta-cell dysfunction (BCD)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Insulin resistance (IR) and beta-cell dysfunction (BCD)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Multiple regression analyses
Number of subjects: 729
Study: 35717635

Group type: COMPARATOR
Intervention: No hygiene recommendations (part 1)
Number of subjects: 9661

Group type: EXPERIMENTAL
Intervention: Twin pregnancy
Number of subjects: 9661

Group type: EXPERIMENTAL
Intervention: Maternal medical conditions
Number of subjects: 9661
Study: 35718119

Group type: EXPERIMENTAL
Intervention: Web-based smoking cessation intervention
Number of subjects: 439
Study: 35718763

Group type: EXPERIMENTAL
Intervention: NoMAD (Normalization Measurement Development questionnaire)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Visual traffic light summary (TLS)
Number of subjects: 56
Study: 35718782

Group type: EXPERIMENTAL
Intervention: PD + Teacher-Wellness (PDT)
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: PD alone (PD)
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control
Number of subjects: 540
Study: 35718845

Group type: EXPERIMENTAL
Intervention: HCMSQ (Hypertrophic Cardiomyopathy Symptom Questionnaire)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HCMSQ
Number of subjects: 0
Study: 35719001

Group type: EXPERIMENTAL
Intervention: 60-minute dosing interval
Number of subjects: 0

Group type: COMPARATOR
Intervention: 30-minute dosing interval
Number of subjects: 0
Study: 35719139

Group type: EXPERIMENTAL
Intervention: BOSB (bean and oats snack bar), 50 g per day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study: 35719155

Group type: EXPERIMENTAL
Intervention: Moderate malnutrition diagnosed in patients with chronic pancreatitis (CP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 66
Study: 35719690

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 35719960

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (100mg/m) + phenelzine (60mg daily)
Number of subjects: 0
Study: 35720061

Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) in patients with benign recurrent vertigo (BRV)
Number of subjects: 2751

Group type: EXPERIMENTAL
Intervention: Right-to-left shunt (RLS) in patients with vestibular migraine (VM)
Number of subjects: 2751

Group type: COMPARATOR
Intervention: Control group (benign paroxysmal positional vertigo, Meniere's disease, vestibular paroxysmia)
Number of subjects: 2751
Study: 35720069

Group type: EXPERIMENTAL
Intervention: SIOP Ependymoma II trial intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Centralized pathology and imaging for diagnosis confirmation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Central neurosurgical and radiological postoperative MRI reviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational study for patients ineligible for interventional strata
Number of subjects: 0
Study: 35720096

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT)
Number of subjects: 14
Study: 35720286

Group type: EXPERIMENTAL
Intervention: Sub-thrombolytic dose of tPA along with ozanimod
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sub-thrombolytic dose of tPA along with vehicle control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ozanimod
Number of subjects: 0
Study: 35720312

Group type: EXPERIMENTAL
Intervention: Tislelizumab plus sequential neoadjuvant chemotherapy
Number of subjects: 80
Study: 35720454

Group type: EXPERIMENTAL
Intervention: Telestroke consultations via telemedicine
Number of subjects: 443
Study: 35720675

Group type: EXPERIMENTAL
Intervention: Smartwatch-smartphone app dyad for 14 days
Number of subjects: 90
Study: 35720727

Group type: EXPERIMENTAL
Intervention: Modified Mediterranean Ketogenic (MMK) diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: American Heart Association (AHA) diet
Number of subjects: 20
Study: 35720980

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 35721046

Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A for inhalation (L-CsA-i)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 35721084

Group type: EXPERIMENTAL
Intervention: Camouflage combined with psychotherapy
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 149
Study: 35721350

Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback for emotion regulation
Number of subjects: 0
Study: 35721744

Group type: EXPERIMENTAL
Intervention: RJX (1.25 mL/kg or 2.5 mL/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NS (control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-diabetic control rats
Number of subjects: 0
Study: 35722047

Group type: EXPERIMENTAL
Intervention: 12-week structured physical activity programme during chemotherapy
Number of subjects: 20
Study: 35722126

Group type: EXPERIMENTAL
Intervention: Physical Activity integrated into learning (daily PA unit of 45 min over 3 years)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control schools (no specific intervention mentioned)
Number of subjects: 3000
Study: 35722590

Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy (MCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 0
Study: 35722822

Group type: EXPERIMENTAL
Intervention: DS-1001 (125-1400 mg orally, twice daily)
Number of subjects: 47
Study: 35722876

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Preprocedural magnetic resonance imaging
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Procedural or antithrombotic management
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Persistence of acquired von Willebrand factor defect
Number of subjects: 84
Study: 35723247

Group type: EXPERIMENTAL
Intervention: None/mild LVOT calcium
Number of subjects: 107

Group type: COMPARATOR
Intervention: Moderate/severe LVOT calcium
Number of subjects: 107
Study: 35723668

Group type: EXPERIMENTAL
Intervention: In-Person Intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Online Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 35723793

Group type: EXPERIMENTAL
Intervention: Pre-operative breast MRI
Number of subjects: 957

Group type: COMPARATOR
Intervention: No pre-operative breast MRI
Number of subjects: 957
Study: 35723922

Group type: EXPERIMENTAL
Intervention: Amnestic MCI
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Nonamnestic MCI
Number of subjects: 76

Group type: COMPARATOR
Intervention: Controls with normal cognition
Number of subjects: 76
Study: 35723961

Group type: EXPERIMENTAL
Intervention: Compressive taping applied over the seroma fluctuation area for 5 days
Number of subjects: 35
Study: 35724253

Group type: EXPERIMENTAL
Intervention: Community-Based Participatory Research (CBPR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human-Centered Design
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBPR and Human-Centered Design
Number of subjects: 0
Study: 35724307

Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supervised Caloric Restriction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 35724470

Group type: EXPERIMENTAL
Intervention: Dynamic Work (DW) intervention
Number of subjects: 0
Study: 35724624

Group type: EXPERIMENTAL
Intervention: Enrolled in clinical trial
Number of subjects: 9516

Group type: COMPARATOR
Intervention: Not enrolled in clinical trial
Number of subjects: 9516
Study: 35724693

Group type: EXPERIMENTAL
Intervention: Optical diagnosis (OD) of polyps with a resect and discard strategy
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Optical diagnosis (OD) of ≤5-mm adenoma
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: OD-histology surveillance interval concordance for ≤5-mm OD
Number of subjects: 525
Study: 35724695

Group type: EXPERIMENTAL
Intervention: EMR with h-APC ablation
Number of subjects: 84
Study: 35724798

Group type: EXPERIMENTAL
Intervention: Befotertinib 50 mg (cohort A)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Befotertinib 75 to 100 mg (cohort B)
Number of subjects: 466
Study: 35725143

Group type: EXPERIMENTAL
Intervention: Weight loss before treatment
Number of subjects: 153

Group type: COMPARATOR
Intervention: Weight stable before treatment
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Weight gain before treatment
Number of subjects: 153
Study: 35725262

Group type: EXPERIMENTAL
Intervention: Healthcare utilization over 1 year
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Primary care consultations
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Imaging
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Paracetamol usage
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Healthcare utilization by risk profile
Number of subjects: 452
Study: 35725407

Group type: EXPERIMENTAL
Intervention: EatsUp® mobile application
Number of subjects: 69
Study: 35725542

Group type: EXPERIMENTAL
Intervention: Standardized prolonged discharge prescription forms plus education
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20000
Study: 35725623

Group type: EXPERIMENTAL
Intervention: Enzyme replacement therapy (ERT) with agalsidase alfa
Number of subjects: 4484
Study: 35725670

Group type: EXPERIMENTAL
Intervention: Cosyntropin-stimulated 17-hydroxyprogesterone (17OHP)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Serum steroid profiling including 21-deoxycortisol and cosyntropin stimulation test with 17OHP
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: NCCAH diagnosis
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy patients in validation cohort
Number of subjects: 65
Study: 35725741

Group type: EXPERIMENTAL
Intervention: Bilateral sensorimotor map of forearm muscles using multiunit activity (MUA) and surface electromyography (EMG) during voluntary contractions of the extensor carpi radialis (ECR) and attempted motions in the flexor carpi radialis (FCR).
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Mapping and comparing left- and right-wrist-extensor-related activity throughout several sessions.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Neural signals at the within-electrode (multiunit) and cross-electrode (network) levels.
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Comparison of somatotopy of active electrodes.
Number of subjects: 1
Study: 35725917

Group type: EXPERIMENTAL
Intervention: Enteral iron supplementation (median cumulative intake 58.5 mg/kg at 28 days, 235.8 mg/kg through 36 weeks)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Parenteral iron supplementation (median cumulative intake 3.1 mg/kg at 28 days, 3.56 mg/kg through 36 weeks)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusions
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 941
Study: 35726133

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate
Number of subjects: 5711
Study: 35726281

Group type: EXPERIMENTAL
Intervention: Biofeedback group
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 88
Study: 35726382

Group type: EXPERIMENTAL
Intervention: Universal family psychosocial risk screening
Number of subjects: 19
Study: 35726608

Group type: EXPERIMENTAL
Intervention: WDR62-related cognitive assessment
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vineland Adaptive Behavior Scales
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Long-term follow-up for progressive ataxia
Number of subjects: 17
Study: 35726748

Group type: EXPERIMENTAL
Intervention: Body composition indices and alanine transaminase
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Models including alanine transaminase alongside body composition measurements
Number of subjects: 2120

Group type: EXPERIMENTAL
Intervention: Final models including five variables: body mass index-standard deviation score, android-to-gynoid-fat ratio, android-regional fat percent, trunk-regional fat percent and alanine transaminase
Number of subjects: 2120
Study: 35726793

Group type: EXPERIMENTAL
Intervention: Combination ipilimumab/nivolumab followed by maintenance nivolumab
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Combination ipilimumab/nivolumab
Number of subjects: 1
Study: 35726803

Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Number of subjects: 0
Study: 35726971

Group type: EXPERIMENTAL
Intervention: Concentrated parenteral nutrition (PN)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Original parenteral nutrition (PN)
Number of subjects: 134
Study: 35727117

Group type: EXPERIMENTAL
Intervention: Social networks intervention, details not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 35727152

Group type: EXPERIMENTAL
Intervention: Knees with KOA
Number of subjects: 4634

Group type: COMPARATOR
Intervention: Knees without KOA
Number of subjects: 4634
Study: 35727196

Group type: EXPERIMENTAL
Intervention: Early mobilisation (1 week post injury)
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Open reduction and internal fixation with a locking plate
Number of subjects: 3179

Group type: COMPARATOR
Intervention: Reverse total shoulder arthroplasty (RTSA)
Number of subjects: 3179
Study: 35727209

Group type: EXPERIMENTAL
Intervention: Hemoglobin to creatinine ratio
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Ejection fraction (EF)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Contrast amount used
Number of subjects: 500
Study: 35727324

Group type: EXPERIMENTAL
Intervention: Quantitative information provided in consultations (average 11,086 words spoken, with a focus on 422 quantitative words).
Number of subjects: 112
Study: 35727334

Group type: EXPERIMENTAL
Intervention: Nurse-led coordinated pathway of care (NLC-RAPN)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Open partial nephrectomy (OPN)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Robot-assisted partial nephrectomy (RAPN)
Number of subjects: 151
Study: 35727343

Group type: EXPERIMENTAL
Intervention: E-scooter accidents during working hours
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: E-scooter accidents during off-working hours
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 170
Study: 35727476

Group type: EXPERIMENTAL
Intervention: KTE-X19
Number of subjects: 0

Group type: COMPARATOR
Intervention: BLIN
Number of subjects: 0

Group type: COMPARATOR
Intervention: INO
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHEMO
Number of subjects: 0
Study: 35727609

Group type: EXPERIMENTAL
Intervention: TaiChi4Joint intervention (12-week remotely delivered tai chi classes via Zoom, 3 times a week)
Number of subjects: 39
Study: 35727618

Group type: EXPERIMENTAL
Intervention: mHealth patch device with AI arrhythmia analysis for AF detection
Number of subjects: 178
Study: 35727622

Group type: EXPERIMENTAL
Intervention: Digitally delivered treatment program for LBP (3 months duration)
Number of subjects: 2593
Study: 35727629

Group type: EXPERIMENTAL
Intervention: neoadjuvant bintrafusp alfa
Number of subjects: 14
Study: 35727633

Group type: EXPERIMENTAL
Intervention: Tumor-infiltrating lymphocytes (TILs) infusion after concurrent chemoradiotherapy (CCRT) plus i.m. IL-2 injections
Number of subjects: 27

Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 27
Study: 35727758

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment according to WHO 2006 child-growth standards; ECD status using the Child Development Evaluation Test, 2nd Edition.
Number of subjects: 1176
Study: 35727802

Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S vaccine
Number of subjects: 477234
Study: 35727876

Group type: EXPERIMENTAL
Intervention: Left Ventricular Noncompaction (LVNC) defined as NC:C ≥2 in at least one segment
Number of subjects: 25590

Group type: EXPERIMENTAL
Intervention: Left Ventricular Noncompaction (LVNC)
Number of subjects: 25590

Group type: COMPARATOR
Intervention: Matched controls (1:10 on sex, gestational age, and weight)
Number of subjects: 25590
Study: 35727884

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 35728046

Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Number of subjects: 0
Study: 35728342

Group type: EXPERIMENTAL
Intervention: de novo metastatic breast cancer (dnMBC)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Age groups (younger than 50, 50-69, 70 years or older)
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: HER2-positive status
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Triple-negative, luminal A-like, and luminal B-like breast cancer subtypes
Number of subjects: 355
Study: 35728621

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 44
Study: 35728746

Group type: EXPERIMENTAL
Intervention: Biologics (including omalizumab, benralizumab, mepolizumab, dupilumab, reslizumab)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Biologics (switching biologics)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Non-anti-immunoglobulin E biologics
Number of subjects: 2793
Study: 35728910

Group type: EXPERIMENTAL
Intervention: Causative bacterial infection
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Causative viral infection
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Mixed bacterial and viral infections
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Unclassified infections
Number of subjects: 188
Study: 35728925

Group type: EXPERIMENTAL
Intervention: Online estimator for predicting bronchopulmonary dysplasia (BPD) severity or death using demographic and clinical data.
Number of subjects: 9181
Study: 35729005

Group type: EXPERIMENTAL
Intervention: Dostarlimab (500 mg IV every 3 weeks for Cycles 1-4, then 1000 mg Q6W) until disease progression or unacceptable toxicity
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dostarlimab
Number of subjects: 67
Study: 35729357

Group type: COMPARATOR
Intervention: Eye-tracking-based test using SRLab-Tobii TX300 Eye tracker®
Number of subjects: 68
Study: 35729365

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 13
Study: 35729429

Group type: EXPERIMENTAL
Intervention: Initial treatment strategies, invasive procedures, revascularisation therapies, and use of mechanical circulatory support devices, including extracorporeal cardiopulmonary resuscitation.
Number of subjects: 400
Study: 35729589

Group type: EXPERIMENTAL
Intervention: EASE intervention delivered by non-specialist facilitators
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: EASE intervention
Number of subjects: 59
Study: 35729620

Group type: EXPERIMENTAL
Intervention: Autogenic drainage (AD)
Number of subjects: 30
Study: 35729673

Group type: EXPERIMENTAL
Intervention: D-allulose (8.5 g consumed before iftar meal)
Number of subjects: 12
Study: 35729736

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training
Number of subjects: 80